: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Teva (TEVA): Baby-Boomers Boost Generics

Wed, 07 Oct 2009 13:34:11 GMT

"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests Stephen Leeb.[More...]

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Tue, 06 Oct 2009 21:44:54 GMT

Momenta Pharma (NASDAQ: MNTA) presented at the 2009 UBS Global Life Sciences Conference about two weeks ago and outlined several key developments for the Company, including an update on the FDA status for M-Enoxaparin.[More...]

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Fri, 02 Oct 2009 16:55:00 GMT

On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP).[More...]

How To Find The Best Potential Profit Plays In The Resurgent M&A And IPO Markets

Tue, 29 Sep 2009 13:52:15 GMT

When Xerox Corp. (NYSE: XRX) yesterday (Monday) unveiled plans to pay $6.4 billion for outsourcing specialist Affiliated Computer Services Inc. (NYSE: ACS), it was just one of four major financing deals with an aggregate value of more than $14 billion announced on the day.[More...]

BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential

Sun, 27 Sep 2009 18:35:16 GMT

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception, and male testosterone deficiency (hypogonadism). The Company’s wholly-owned lead product is LibiGel (transdermal testosterone gel), which is in Phase 3 clinical development by BioSante under dual Special Protocol Assessments (SPAs) for the treatment of female sexual dysfunction (FSD).[More...]

Another Drawback Of ETFs

Tue, 01 Sep 2009 15:14:09 GMT

Despite the title of this post I'm sure that most people that have read my stuff know that I am a huge fan of ETFs. They allow people willing to spend the time to build very sophisticated portfolios that by and large avoid single stock risk. The broader funds allow for simple and cheap beta for people who for whatever reason do not build portfolios with narrower funds in the capacity I write about. All that noted there are drawbacks to the product, every product has drawbacks. One written about previously is that it can be more difficult to capture a good dividend yield. Some of the "dividend" ETFs are (were?) heavy in financials and quite a few of the WisdomTree funds have very lumpy dividends.[More...]

Emerging Market Or Pharma

Tue, 25 Aug 2009 18:52:22 GMT

The shape of the global market for pharmaceuticals is undergoing a rapid change. As recently as 2006, more than half of the market growth was in the United States. This data comes from IMS Health, a consultancy that is a leading provider of pharmaceutical trends.[More...]

Merck (MRK) Wins Legal Battle

Thu, 20 Aug 2009 23:04:13 GMT

Merck (MRK) received a favorable ruling in a major patent-infringement suit yesterday against the largest generic player, Teva Pharmaceuticals (TEVA), on its top-selling drug Singulair. Teva was seeking the Food and Drug Administration’s (FDA) approval for selling a generic version of the drug for asthma and allergic rhinitis. The litigation has been continuing since Merck sued Teva in February 2007. During the second quarter of 2009, Singulair recorded worldwide sales of $1.3 billion, up 16% from the year-ago period. The drug had total sales of $4.3 billion in fiscal 2008, accounting for about 18% of Merck’s total revenue. Defending Singulair’s patent was thus quite crucial for Merck. We[More...]

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Lawyers target Israeli medical supplier

Tue, 13 Oct 2009 17:20:00 GMT

Lawyers target Israeli medical supplier[More...]

Business Highlights

Wed, 19 Aug 2009 22:45:00 GMT

Stocks turn higher on jump in energy demand
NEW YORK (AP) - The stock market extended a streak of erratic trading Wednesday, rebounding from early losses and rising moderately after a drop in oil inventories lifted hopes for an economic recovery.
WASHINGTON (AP) - The U.S. pulled back the veil on Switzerland's famed tradition of banking secrecy Wednesday, winning an agreement for banking giant UBS AG to disclose the names of 4,450 American clients suspected of hiding assets in Swiss accounts.

: iStockAnalyst.com Symbols Feed

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Teva (TEVA): Baby-Boomers Boost Generics

Momenta Pharma (MNTA): Timing Uncertain, Approval Likely for M-Enoxaparin

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

How To Find The Best Potential Profit Plays In The Resurgent M&A And IPO Markets

BioSante (NASDAQ: BPAX): LibiGel Provides Big Upside Potential

Another Drawback Of ETFs

Emerging Market Or Pharma

Merck (MRK) Wins Legal Battle

Spotlight On: Biotech

Lawyers target Israeli medical supplier

Business Highlights

Teva Q2 Net Income Decreases

Women underestimate menopause symptoms

Teva and Antares Win FDA Approval for Needle-Free Device

Teva Q1 Net Income Surges

COPAXONE(R) Approved By Health Canada for Patients With Clinically Isolated Syndrome (CIS) Suggestive of Multiple Sclerosis (MS)

Cubist Files Patent Infringement Lawsuit Against Teva Parenteral Medicines

BRIEF: Bedford Employer Named Israel's Strongest Company

BRIEF: Teva Pharmaceutical Industries Receives Approval to Buy Barr Laboratories in Forest

Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets

Teva Reports Third Quarter 2009 Results

MichBio Expo &Amp; Conference Exhibitors Profiled

Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement

Teva Provides Update on Generic Seroquel® Litigation

Teva Provides Update on Generic Evista® Litigation

Teva Women's Health Announces CopewithMenopause.Com Relaunch Just in Time for Menopause Awareness Month ; New Design Features Dynamic Content Including Videos and Resources to Help Women and Their Families Deal With the Impact of Menopause

The First Israel Fund, Inc. Announces Performance Data and Portfolio Composition

Teva Provides Update on Generic Singulair® Litigation

StockPreacher.com Issues Trading Outlook for Cell Therapeutics Inc.